Navigation Links
Drug Reduces Airway Mucus in Preclinical Asthma Model
Date:2/19/2008

SAN FRANCISCO, Feb. 19 /PRNewswire/ -- Inverseon, Inc. (http://www.inverseon.com) announces the publication of a rapid communication of groundbreaking research led by Professor Richard Bond of the University of Houston, Inverseon's Scientific Founder. In the March article by Nguyen, et. al., in the American Journal of Respiratory Cell and Molecular Biology 2008; 38: 256-262, entitled, "Chronic Exposure to Beta-Blockers Attenuates Inflammation and Mucin Content in a Murine Asthma Model," airway mucus hypersecretion and inflammation were almost completely reversed upon treatment with certain beta blockers. The Journal commented that, "This research may result in a paradigm shift in the treatment of asthma. This research demonstrates the importance that duration of therapy has on clinical and physiologic responses."

"It is gratifying to see these findings, which were originally described in Prof. Bond's laboratory, confirmed in a respected independent laboratory," commented William J. Garner, MD, Chairman of Inverseon.

About Inverseon, Inc.

Inverseon's product development programs target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as asthma, COPD and pulmonary hypertension. Inverseon was founded based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects "Paradoxical Pharmacology," based on the divergence of acute versus chronic effects of certain drugs in chronic diseases. For further information, please visit Inverseon's website at http://www.inverseon.com.

Forward-Looking Statement

This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

Contact:

William J. Garner, MD

bill@inverseon.com

http://www.inverseon.com

(212) 222-1188

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Inverseon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Landfill mining reduces environmental impact of growing waste
2. Landfill mining reduces environmental impact of growing waste
3. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
4. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
5. Heavier hydrogen on the atomic scale reduces friction
6. Genmab Announces Encouraging Preclinical Data for ofatumumab
7. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
8. Preclinical Research on Coronary Stent with CeloNova BioSciences Polyzene(R)- F Nanocoating Receives Award at CIRSE 2007
9. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
10. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
11. Arpida Presents Preclinical Data on AR-2474 at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2017)... ROCKVILLE, Md. , Aug. 11, 2017 ... in a New York Times article regarding ... 9.2 billion, according to Kalorama Information.  The ... an App for That"  used information ... Remote Patient Monitoring & Telemedicine Market  (Sleep, ...
(Date:8/10/2017)... (PRWEB) , ... August 09, 2017 , ... ... the classroom next week-- as students. From August 14th through the 16th, the ... institute, which debuted in the summer of 2016, provides Philadelphia-based middle school educators ...
(Date:8/10/2017)... ... August 10, 2017 , ... DrugDev and ... webinar to demonstrate how Good Clinical Practice (GCP) can be used throughout ... addition the webinar will discuss the importance of GCP compliance, how sites are affected ...
(Date:8/8/2017)... ... August 08, 2017 , ... HumanZyme ... in human cells, today announced the launch of HumanKine® Interferon beta ... I family of interferons that activate Th1-type innate immune responses against viral and bacterial ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):